Evidence map›Paper›PMID 31186314›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Alex B Blair, Victoria M Kim, Stephen T Muth, May Tun Saung, Nathalie Lokker, Barbara Blouw, Todd D Armstrong, Elizabeth M Jaffee, Takahiro Tsujikawa, Lisa M Coussens and 4 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 78 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Alex B BlairThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-3297-2299
Victoria M KimThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Stephen T MuthThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
May Tun SaungThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Nathalie LokkerAstraZeneca, Gaithersburg, Maryland.
Barbara BlouwHalozyme Therapeutics, Inc., San Diego, California.
Todd D ArmstrongThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Elizabeth M JaffeeThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Takahiro TsujikawaDepartment of Otolaryngology, Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID 0000-0003-1647-342X
Lisa M CoussensDepartment of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Jin HeThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9149-2247
Richard A BurkhartThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Christopher L WolfgangThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Lei ZhengThe Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. lzheng6@jhmi.edu.
Johns Hopkins University · USOregon Health & Science University · USAstraZeneca (Japan) · JPHalozyme Therapeutics (United States) · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Clinical and Laboratory Research Training for Surgical OncologistsT32CA126607 · NCI · JOHNS HOPKINS UNIVERSITY · PI CAMERON, ANDREW M. · 2008 to 2024
$6.0M
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical TrialR01CA197296 · NCI · JOHNS HOPKINS UNIVERSITY · PI William Reece Burns, Eric Christenson · 2015 to 2026
$5.7M
Interrogate the interaction between tumor cells and nerves in the tumor microenvironment of pancreatic cancerR01CA169702 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ZHENG, LEI · 2013 to 2023
$3.6M
Dissecting the mechanisms of immune tolerance within the pancreatic tumor's microK23CA148964 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHENG, LEI · 2010 to 2014
$888k
NCI NIH HHS K23 CA148964NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA169702NCI NIH HHS R01 CA197296NCI NIH HHS T32 CA126607
6 · The paper itself

Abstract

purposeMyeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells through modifying a specific stromal component. EXPERIMENTAL

designA murine model of metastatic PDAC treated with an irradiated whole-cell PDAC vaccine and PDAC specimens from patients treated with the same type of vaccine were used to assess the immune-modulating effect of stromal hyaluronan (HA) degradation by PEGPH20.

resultsTargeting stroma by degrading HA with PEGPH20 in combination with vaccine decreases CXCL12/CXCR4/CCR7 immunosuppressive signaling axis expression in cancer-associated fibroblasts, myeloid, and CD8

conclusionsThis study represents the first to dissect signaling cascades following PDAC stroma remodeling via HA depletion, suggesting this not only overcomes a physical barrier for immune cell trafficking, but alters myeloid function leading to downstream selective increases in effector memory T-cell infiltration and antitumor activity.

Indexed as

AnimalsCancer-Associated FibroblastsCancer VaccinesCarcinoma, Pancreatic DuctalCD8-Positive T-LymphocytesCell Line, TumorCell MovementChemokinesFemaleHumansImmunologic MemoryImmunosuppression TherapyLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLMice, TransgenicCancer VaccinesChemokines

Identifiers

PMID31186314
PMCPMC6726532
OpenAlexW2952690424

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.